Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;24(1):9-23.
doi: 10.1177/1089253219898985. Epub 2020 Jan 12.

Heart Transplantation After Ventricular Assist Device Therapy: Benefits, Risks, and Outcomes

Affiliations
Review

Heart Transplantation After Ventricular Assist Device Therapy: Benefits, Risks, and Outcomes

Nirvik Pal et al. Semin Cardiothorac Vasc Anesth. 2020 Mar.

Abstract

Heart transplantation is an established treatment for end-stage heart failure. Due to the increase in demand and persistent scarcity of organ, mechanical circulatory devices have played a major role in therapy for advanced heart failure. Usage of left ventricular assist device (LVAD) has gone up from 6% in 2006 to 43% in 2013 as per the United Network of Organ Sharing database. Majority of patients presenting for a heart transplantation are often bridged with an assist device prior for management of heart failure while on wait-list. On one hand, it is well established that LVADs improve survival on wait-list; on the other hand, the effect of LVAD on morbidity and survival after a heart transplantation is still unclear. In this article, we review the available literature and attempt to infer the outcomes given the risks and benefits of heart transplantation with prior LVAD patients.

Keywords: heart failure; heart transplantation; left ventricular assist devices; outcomes; survival.

PubMed Disclaimer

MeSH terms

LinkOut - more resources